1. The company is pricing the stock at $1.50 per share before the underwriting discounts. The public offering is expected to raise $20 million in gross proceeds.
2. Underwriters have the ability to purchase up to 2 million additional shares of common stock over a 30-day period.
3. The acting joint book-running managers are Cowen and Canaccord; Suntrust Robinson Humphrey is the lead manager.
4. ConforMIS expects to close the offering around Jan. 29.
5. ConforMIS owns or exclusively in-licenses around 420 issued patents and pending patent applications related to its proprietary iFit Image-to-Implant technology and customized implants for joint replacement.
More articles on orthopedic devices:
41 spine devices receive FDA clearance in December 2017
Dr. Todd Lanman demonstrates new lumbar spine fusion implant
Implanet’s JAZZ sales increased 30% in 2017
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
